These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17561341)

  • 1. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Reni M; Cereda S; Galli L
    Cancer Lett; 2007 Oct; 256(1):25-8. PubMed ID: 17561341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):361-7. PubMed ID: 16807732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    Reni M; Cordio S; Milandri C; Passoni P; Bonetto E; Oliani C; Luppi G; Nicoletti R; Galli L; Bordonaro R; Passardi A; Zerbi A; Balzano G; Aldrighetti L; Staudacher C; Villa E; Di Carlo V
    Lancet Oncol; 2005 Jun; 6(6):369-76. PubMed ID: 15925814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
    Reni M; Cereda S; Bonetto E; Viganò MG; Passoni P; Zerbi A; Balzano G; Nicoletti R; Staudacher C; Di Carlo V
    Cancer Invest; 2007; 25(7):594-8. PubMed ID: 17852117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Reni M; Cereda S; Rognone A; Belli C; Ghidini M; Longoni S; Fugazza C; Rezzonico S; Passoni P; Slim N; Balzano G; Nicoletti R; Cappio S; Doglioni C; Villa E
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):115-23. PubMed ID: 21626049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cereda S; Passoni P; Reni M; Viganò MG; Aldrighetti L; Nicoletti R; Villa E
    Cancer; 2010 May; 116(9):2208-14. PubMed ID: 20187098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
    Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
    Reni M; Passoni P; Panucci MG; Nicoletti R; Galli L; Balzano G; Zerbi A; Di Carlo V; Villa E
    J Clin Oncol; 2001 May; 19(10):2679-86. PubMed ID: 11352960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gemcitabine-based combinations in inoperable pancreatic cancers].
    Louvet C; André T; Artru P
    Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
    Reni M; Passoni P; Bonetto E; Balzano G; Panucci MG; Zerbi A; Ronzoni M; Staudacher C; Villa E; Di Carlo V
    Oncology; 2005; 68(2-3):239-45. PubMed ID: 16015040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
    Reni M; Bonetto E; Cordio S; Passoni P; Milandri C; Cereda S; Spreafico A; Galli L; Bordonaro R; Staudacher C; Di Carlo V; Johnson CD
    Pancreatology; 2006; 6(5):454-63. PubMed ID: 16847383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
    Reni M; Cereda S; Balzano G; Passoni P; Rognone A; Zerbi A; Nicoletti R; Mazza E; Arcidiacono PG; Di Carlo V; Villa E
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1253-9. PubMed ID: 19381632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
    Cantore M; Fiorentini G; Luppi G; Rosati G; Caudana R; Piazza E; Comella G; Ceravolo C; Miserocchi L; Mambrini A; Del Freo A; Zamagni D; Rabbi C; Marangolo M
    J Chemother; 2004 Dec; 16(6):589-94. PubMed ID: 15700852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
    Mambrini A; Bassi C; Torri T; Orlandi M; Fiorentini G; Cantore M
    Pancreas; 2011 Aug; 40(6):983-4. PubMed ID: 21562443
    [No Abstract]   [Full Text] [Related]  

  • 17. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
    Mambrini A; Pacetti P; Del Freo A; Seta RD; Pezzuolo D; Torri T; Orlandi M; Tartarini R; Cantore M
    Anticancer Res; 2009 May; 29(5):1547-9. PubMed ID: 19443364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
    Zygulska AL; Pawlega J
    Przegl Lek; 2008; 65(12):825-8. PubMed ID: 19441672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.